Skip to main content
. 2026 Feb 1;18(3):488. doi: 10.3390/cancers18030488
VEGF Vascular endothelial growth factor
Bev Bevacizumab
GB Glioblastoma
FLAIR Fluid-attenuated inversion recovery
neoBev Neoadjuvant bevacizumab
T1-Gd T1-weighted imaging with gadolinium enhancement
mOS Median overall survival
RT Radiation therapy
TMZ Temozolomide
PFS Progression-free survival
MRI Magnetic resonance imaging
EOR Extent of resection
GTR Gross total resection